News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
207,463 Results
Type
Article (20035)
Company Profile (117)
Press Release (187302)
Multimedia
Podcasts (41)
Webinars (14)
Section
Business (64112)
Career Advice (837)
Deals (9104)
Drug Delivery (78)
Drug Development (18923)
Employer Resources (145)
FDA (3405)
Job Trends (6107)
News (95769)
Policy (7147)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1504)
Academic (2)
Accelerated approval (8)
Adcomms (16)
Allergies (29)
Alliances (17463)
ALS (54)
Alzheimer's disease (683)
Antibody-drug conjugate (ADC) (108)
Approvals (3520)
Artificial intelligence (252)
Autoimmune disease (47)
Automation (22)
Bankruptcy (52)
Best Places to Work (4925)
BIOSECURE Act (12)
Biosimilars (67)
Biotechnology (65)
Bladder cancer (48)
Brain cancer (15)
Breast cancer (197)
Cancer (1366)
Cardiovascular disease (150)
Career advice (755)
Career pathing (37)
CAR-T (96)
CDC (19)
Cell therapy (252)
Cervical cancer (10)
Clinical research (15350)
Collaboration (755)
Compensation (168)
Complete response letters (14)
COVID-19 (1013)
CRISPR (48)
C-suite (484)
Cystic fibrosis (54)
Data (1910)
Decentralized trials (1)
Denatured (23)
Depression (56)
Diabetes (134)
Diagnostics (2488)
Digital health (17)
Diversity (10)
Diversity, equity & inclusion (37)
Drug discovery (118)
Drug pricing (59)
Drug shortages (4)
Duchenne muscular dystrophy (78)
Earnings (15583)
Editorial (24)
Employer branding (23)
Employer resources (122)
Events (31246)
Executive appointments (562)
FDA (4280)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (5)
Frontotemporal dementia (6)
Funding (706)
Gene editing (86)
Generative AI (28)
Gene therapy (191)
GLP-1 (356)
Government (1408)
Guidances (123)
Healthcare (4965)
HIV (28)
Huntington's disease (26)
IgA nephropathy (23)
Immunology and inflammation (54)
Immuno-oncology (10)
Indications (27)
Infectious disease (1110)
Inflammatory bowel disease (75)
Inflation Reduction Act (10)
Influenza (39)
Intellectual property (63)
Interviews (118)
IPO (3693)
IRA (17)
Job creations (1315)
Job search strategy (643)
JPM (29)
Kidney cancer (2)
Labor market (82)
Layoffs (205)
Leadership (19)
Legal (1200)
Liver cancer (27)
Longevity (10)
Lung cancer (174)
Lymphoma (150)
Machine learning (19)
Management (43)
Manufacturing (311)
MASH (31)
Medical device (2689)
Medtech (2707)
Mergers & acquisitions (5822)
Metabolic disorders (346)
Multiple sclerosis (69)
NASH (9)
Neurodegenerative disease (126)
Neuropsychiatric disorders (29)
Neuroscience (1145)
Neurotech (1)
NextGen: Class of 2026 (2114)
Non-profit (1703)
Now hiring (64)
Obesity (178)
Opinion (137)
Ovarian cancer (36)
Pain (69)
Pancreatic cancer (46)
Parkinson's disease (90)
Partnered (21)
Patents (100)
Patient recruitment (116)
Peanut (15)
People (28129)
Pharmaceutical (25)
Pharmacy benefit managers (2)
Phase 1 (4498)
Phase 2 (6335)
Phase 3 (6097)
Pipeline (1509)
Policy (104)
Postmarket research (559)
Preclinical (2557)
Press Release (61)
Prostate cancer (65)
Psychedelics (28)
Radiopharmaceuticals (68)
Rare diseases (262)
Real estate (2559)
Recruiting (58)
Regulatory (5741)
Reports (40)
Research institute (1303)
Resumes & cover letters (108)
Rett syndrome (3)
RNA editing (9)
RSV (41)
Schizophrenia (57)
Series A (131)
Series B (88)
Service/supplier (7)
Sickle cell disease (38)
Special edition (13)
Spinal muscular atrophy (57)
Sponsored (17)
Startups (2027)
State (1)
Stomach cancer (6)
Supply chain (38)
Tariffs (16)
The Weekly (18)
Vaccines (306)
Venture capital (60)
Weight loss (109)
Women's health (36)
Worklife (18)
Date
Last 7 days (202)
Last 30 days (773)
Last 365 days (9546)
2026 (989)
2025 (9704)
2024 (11449)
2023 (13015)
2022 (15610)
2021 (17741)
2020 (16355)
2019 (15101)
2018 (10899)
2017 (10360)
2016 (10242)
2015 (10945)
2014 (8075)
2013 (7008)
2012 (7422)
2011 (7598)
2010 (7058)
Location
Africa (336)
Alabama (34)
Alaska (4)
Arizona (89)
Arkansas (4)
Asia (11677)
Australia (2029)
California (3254)
Canada (1055)
China (297)
Colorado (164)
Connecticut (103)
Delaware (177)
Europe (30310)
Florida (490)
Georgia (93)
Hawaii (2)
Idaho (12)
Illinois (222)
India (35)
Indiana (266)
Iowa (12)
Japan (169)
Kansas (42)
Kentucky (12)
Louisiana (8)
Maine (7)
Maryland (328)
Massachusetts (2714)
Michigan (129)
Minnesota (172)
Mississippi (5)
Missouri (46)
Montana (5)
Nebraska (12)
Nevada (23)
New Hampshire (16)
New Jersey (982)
New Mexico (16)
New York (1108)
North Carolina (531)
North Dakota (9)
Northern California (1668)
Ohio (111)
Oklahoma (9)
Oregon (20)
Pennsylvania (542)
Puerto Rico (6)
Rhode Island (16)
South America (398)
South Carolina (8)
Southern California (1130)
Tennessee (62)
Texas (450)
United States (12288)
Utah (71)
Vermont (1)
Virginia (84)
Washington D.C. (32)
Washington State (262)
West Virginia (1)
Wisconsin (75)
Wyoming (1)
207,463 Results for "sage science".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Sage’s Search for Lifeline Ran Into Defiant Biogen CEO
After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was searching for a path forward at the end of December 2024. Biogen CEO Chris Viehbacher spied a possible deal, but the smaller company wasn’t interested.
July 3, 2025
·
3 min read
·
Annalee Armstrong
Layoffs
Sage Sacks Entire Staff After Supernus Buyout
As of Apr. 22, Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks after Maryland’s Supernus Pharmaceuticals acquired Sage for up to $795 million.
June 30, 2025
·
1 min read
·
Tristan Manalac
Legal
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
August 1, 2025
·
9 min read
Neuroscience
Biogen Submits Offer to Buy Embattled Partner Sage
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.
January 13, 2025
·
3 min read
·
Heather McKenzie
Mergers & acquisitions
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
January 27, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in CNS.” Supernus’ offer beats Biogen’s unsolicited bid of about $7.22 per share, which arrived with a thud in late January.
June 16, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Sage Therapeutics Announces Second Quarter 2025 Financial Results
July 30, 2025
·
16 min read
Editorial
Embattled Sage Dealt Deeper Blow With Huntington’s Failure
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts to question the biotech’s future profitability.
November 25, 2024
·
4 min read
·
Heather McKenzie
Podcast
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees more action with new company launches, IPOs and fresh data; and experts get ready for an important era in the Duchenne muscular dystrophy space.
January 29, 2025
·
1 min read
·
Heather McKenzie
1 of 20,747
Next
